Transparency Notification from Shareholders
Transparency Notification from Shareholders
Ghent, Belgium - Sequana Medical NV (Euronext Brussels: SEQUA), a leader in treating drug-resistant fluid overload in liver disease, heart failure, and cancer, has announced a recent transparency notification regarding shareholder voting rights. The notification concerns the number of voting rights attributed to specific shares, as detailed below.
Notification Details
The notification reflects changes in the voting rights held by Société Fédérale de Participations et d'Investissement SA, along with its affiliated entities. The reason for this notification is the acquisition or transfer of voting securities, which has altered the number of voting rights held.
Voting Rights Breakdown
Aggregate number of shares and voting rights held: 3,285,134 shares, which accounts for 6.01% of the total outstanding shares. The total number of outstanding shares for the Company is 54,671,074, each conferring one voting right.
Significance of the Notification
On June 3, 2025, Belfius Insurance's holdings dropped below the 3% threshold, impacting the shareholdings of both Belfius Insurance and SFPI-FPIM, which jointly account for 6.01% of the total voting rights. This adjustment highlights the dynamic nature of share distributions and how they can influence corporate governance.
About Sequana Medical
Sequana Medical is revolutionizing treatment for fluid overload, which poses severe risks to patients with liver disease, heart failure, and cancer. Traditional diuretics often fail for these patients, necessitating innovative solutions like the alfapump® and DSR® systems. These therapies aim to alleviate the burdens associated with diuretic-resistant fluid overload, promising not just clinical improvements but also enhanced quality of life.
Recent Achievements and Future Plans
The Company received FDA approval for the alfapump System, marking a significant milestone in the treatment of recurrent ascites due to liver cirrhosis. With plans to launch in the United States by Q3 2025, Sequana Medical is poised to leverage a targeted specialty sales force to access key liver transplant centers.
Commitment to Effective Medical Solutions
Sequana Medical’s research, such as the promising results from the RED DESERT and SAHARA studies, continues to underline the efficacy of its treatments. These findings support DSR's potential in managing cardiorenal syndrome, showcasing the importance of their ongoing clinical trials.
Upcoming Initiatives
Sequana is dedicated to expanding its offerings in the field of fluid management therapies. Aiming to bridge the gap in effective treatment options, Sequana Medical is committed to continuous research and innovation in this vital health area.
Contact Information
For more information, please contact:
Sequana Medical
Investor relations
E: IR@sequanamedical.com
T: +32 9 292 8065
Frequently Asked Questions
What is the purpose of Sequana Medical's transparency notification?
The transparency notification informs stakeholders about changes in the voting rights related to specific shareholders, ensuring compliance with regulatory standards.
How many voting rights does the Société Fédérale de Participations et d'Investissement SA hold?
Société Fédérale de Participations et d'Investissement SA holds 3,285,134 voting rights, equivalent to 6.01% of the total outstanding shares.
What recent developments has Sequana Medical achieved?
Sequana Medical recently received FDA approval for its alfapump System for treating liver-related recurrent ascites, a significant advancement for the company.
When does Sequana Medical plan to commercialize the alfapump in the US?
The company plans to begin commercial operations for the alfapump System in the US by Q3 2025.
What innovations does Sequana Medical offer to patients?
Sequana Medical is focused on addressing fluid overload in patients with liver disease, heart failure, and cancer through innovative solutions like alfapump® and DSR® therapy, enhancing their quality of life.
